ARTL Artelo Biosciences, Inc. stock chart & analysis
Conviction 45HealthcareScan · Tue, Nov 10, 2026Artelo Biosciences, Inc. (ARTL) closed at $2.40 (+15.94%) on Nov 10, 2026. Its latest daily candle is a bullish marubozu. Price is below its 50-day and below its 200-day moving average. RSI(14) 42, RS Rating 5, -98.8% from its 52-week high, -80.3% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why ARTL moved
From the StockSetups movers recaps that covered ARTL, newest first. A recap states what was known that day.
- Close+75.2%
The catalyst is clearly identified.
Top Stock Movers Sept 23, 2026: BENF, WHLR, VSA →
Financials as of Tue, Jun 30, 2026 · quarterly.
ARTL technical analysis
Trend
ARTL is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 35.5% below the 50-day ($3.72) and 87.0% below the 200-day ($18.44). ADX(14) at 22 points to a moderate trend. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 42, in the bearish half of its range. The MACD histogram is positive. Its RS Rating of 5 puts its weighted 12-month performance ahead of about 5% of the US market.
Volume and volatility
Volume on the latest session ran 0.7× its 20-day average. It trades about $85,159 a day on average. ATR(14) is $0.3564, 14.8% of price — its typical daily range. Bollinger Bands are in a squeeze (2 sessions) — volatility is compressed. On-balance volume is trending down. Chaikin Money Flow (-0.36) shows distribution.
Key levels
The 52-week range is $1.91 to $199.10; price is 98.8% below the high and 25.7% above the low. The VWAP anchored at the 52-week high is $32.78, above price.
Performance
ARTL returned +0.0% (1 week), -22.8% (1 month), -67.3% (3 months), -90.0% (6 months), -89.0% (1 year), -80.3% (year to date).
About Artelo Biosciences, Inc.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Pharmaceutical Preparations · Listed 2015 · 7 employees
SEC filings
EDGAR filings in ARTL · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.